Bind19
Relapsed B-cell Acute Lymphoblastic Leukemia, Childhood
Shenzhen BinDeBio Ltd.Phase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Relapsed B-cell Acute Lymphoblastic Leukemia, Childhood cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VINCRISTINE SULFATE St. Jude Children's Research Hospital | Phase 3 | A |
PEGASPARGASE St. Jude Children's Research Hospital | Phase 3 | A |
MERCAPTOPURINE ANHYDROUS St. Jude Children's Research Hospital | Phase 3 | A |
Cyclophosphamide St. Jude Children's Research Hospital | Phase 3 | BBB |
Cytosin-Arabinosid St. Jude Children's Research Hospital | Phase 3 | BBB |
View all 44 →
Same molecule, other indications
Bind19 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →